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Aims To assess the joint influence of inflammatory biomarkers on the risk of incident atrial fibrillation (AF) in women.
Methods
and results
We performed a prospective cohort study among women participating in the Women’s Health Study. All women
were free of AF at study entry and provided a baseline blood sample assayed for high-sensitivity C-reactive
protein, soluble intercellular adhesion molecule-1, and fibrinogen. To evaluate the joint effect of these three bio-
markers, an inflammation score was created that ranged from 0 to 3 and reflected the number of biomarkers in
the highest tertile per individual. During a median follow-up of 14.4 years, 747 of 24 734 women (3.0%) experienced
a first AF event. Assessed individually, all three biomarkers were associated with incident AF, even after adjustment
for traditional risk factors. When combined into an inflammation score, a strong and independent relationship
between inflammation and incident AF emerged. Across increasing inflammation score categories, there were
1.66, 2.22, 2.73, and 3.25 AF events per 1000 person-years of follow-up. The corresponding hazard ratios (95%
confidence intervals) across inflammation score categories were 1.0, 1.22 (1.00–1.49), 1.32 (1.06–1.65), and 1.59
(1.22–2.06) (P for linear trend 0.0006) after multivariable adjustment.
Conclusion In this large-scale prospective study among women without a history of cardiovascular disease, markers of systemic
inflammation were significantly related to AF even after controlling for traditional risk factors.
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and
its prevalence in the general population is increasing rapidly.1– 3
The importance of AF is further underscored through its associ-
ation with death, stroke, heart failure, cognitive dysfunction, and
a reduced quality of life.4 –8 As treatment of established AF is of
limited long-term success and carries significant risks,9,10 character-
izing potentially modifiable risk factors for AF has substantial clini-
cal relevance.
Although several small, mainly cross-sectional studies found
increased levels of high-sensitivity C-reactive protein in patients
with prevalent AF,11,12 it remains unclear whether inflammation
has a causal role in the development of AF. In one of the first pro-
spective studies, high-sensitivity C-reactive protein levels in the
highest quartile were associated with a 31% increased risk of inci-
dent AF among elderly individuals.13 This relationship was recently
confirmed in an analysis from the Framingham Heart Study.14 Both
of these studies included participants with prevalent cardiovascular
disease at baseline; and therefore, associations could be due in part
to well-established associations between inflammation and preva-
lent cardiovascular conditions that predispose to AF.15 Currently,
prospective data on the association between inflammation and
AF in apparently healthy populations is limited,16 as is data on
inflammatory biomarkers other than high-sensitivity C-reactive
protein.17,18
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The ongoing Women’s Health Study (WHS) presents a unique
opportunity to prospectively examine the joint relationships
between three markers of inflammation (high-sensitivity C-reactive
protein, soluble intercellular adhesion molecule 1 (sICAM-1), and
fibrinogen) and incident AF among 24 734 women free of cardio-
vascular disease and AF at baseline.
Methods
Participants
All study subjects were participants of the WHS, a completed random-
ized trial evaluating the risks and benefits of low-dose aspirin and
vitamin E in the primary prevention of cardiovascular disease and
cancer. Details of the study design have been described previously.19
Briefly, beginning in 1993, 39 876 female health professionals in the
United States who were 45 years or older and free of cardiovascular
disease, cancer or other major illnesses were randomized to receive
100 mg aspirin every other day, 600 IU vitamin E every other day,
both agents or placebo. Randomized treatment ended on March 31,
2004, and women were invited to participate in continued observa-
tional follow-up.
Women participating in the observational follow-up represented the
target population for this study. Blood samples drawn at randomization
were available for 25 883 of these women. Of these, 565 and 3 women
were found to have AF and cardiovascular disease at study entry,
respectively, and 581 women had incomplete data for high-sensitivity
C-reactive protein, sICAM-1 or fibrinogen. Excluding these partici-
pants left 24 734 for the present analysis. Follow-up for all women
started at randomization and was truncated on 2 March 2009. The
study was approved by the institutional review board of Brigham and
Women’s Hospital, Boston, and was monitored by an external data
and safety monitoring board.
Laboratory measurements
Three inflammatory markers were selected based on prior evidence of
association with cardiovascular events and availability in the WHS.20,21
Plasma high-sensitivity C-reactive protein was measured with a vali-
dated high-sensitivity immunoturbidimetric method (Denka Seiken,
Niigata, Japan). sICAM-1 was assayed by quantitative sandwich ELISA
(R&D Systems, Minneapolis, MN) with a reproducibility of 8.9 and
6.4% at concentrations of 171.8 and 289.1 ng/mL, respectively. Fibrino-
gen levels were measured using an immunoturbidimetric assay, which
is a mass-based assay with international standards (Kamiya Biomedical,
Seattle, WA).22
Study variables
Information on baseline variables was collected using mailed question-
naires. Follow-up questionnaires asking participants about study out-
comes and other information were sent every six months during the
first year and every 12 months thereafter. Covariates of interest that
were assessed at study entry included age, blood pressure, smoking,
diabetes, race/ethnicity, body mass index, exercise, and alcohol
consumption.
Ascertainment of incident atrial fibrillation
Women were asked to report diagnoses of incident AF at baseline, 48
months, and then annually thereafter.23,24 Beginning on 19 September
2006, women enrolled in the continued observational follow-up who
reported an incident AF event on at least one yearly questionnaire
were sent an additional questionnaire to confirm the episode and
collect additional information. They were also asked for permission
to review their medical records, particularly available electrocardio-
grams, rhythm strips, 24 h electrocardiograms and information on
cardiac structure and function. For all deceased participants who
reported AF during the trial and extended follow-up period, we con-
tacted family members to obtain consent and additional relevant infor-
mation. An endpoint committee of physicians reviewed medical
records for reported events according to pre-defined criteria. An inci-
dent AF event was confirmed if there was electrocardiographic evi-
dence of AF or if a medical report clearly indicated a personal
history of AF. The earliest date in the medical records when documen-
tation was believed to have occurred was set as the date of onset of
AF. Only confirmed events are included in the present report.
Inflammation score
Simultaneous assessment of multiple inflammatory biomarkers may
provide further insights in the relationship between inflammation and
incident AF. To evaluate whether a multimarker approach using high-
sensitivity C-reactive protein, sICAM-1, and fibrinogen provided addi-
tive information on the risk of incident AF, two separate analyses were
performed. First, an inflammation score was created, where we a priori
specified that one point would be added to the score of an individual
woman for every biomarker in the highest tertile. We used tertiles
instead of quartiles in order to have enough events in the highest
inflammation score category. In a sensitivity analysis, biomarker-
specific medians were used to create the score. As inflammatory
markers are known to be interrelated, we used the first component
of a principal component analysis of logarithmically transformed bio-
marker levels as a second method to capture common variation
between different biomarkers.25 The first principal component is the
linear combination of markers, similar to a weighted average that
explains the most total variance in the inflammatory markers and
thus represents a summary measure of inflammation.
Statistical analysis
Baseline characteristics across inflammation score categories were
compared using Kruskal–Wallis tests for continuous variables and x2
tests for categorical variables. Spearman correlation coefficients
were used to assess the correlation between biomarkers. To deter-
mine whether there was a gradient of risk between individual bio-
markers and incident AF, the study population was categorized into
approximate tertiles according to plasma levels of high-sensitivity
C-reactive protein, sICAM-1, and fibrinogen. We constructed Cox
proportional hazards models to compare hazard ratios (HRs) and
95% confidence intervals (CIs) across biomarker tertiles. We also
examined biomarkers as continuous variables. All biomarkers were
log-transformed for analysis to improve the normality of their distri-
butions as well as the linearity of the association with AF. We tested
for deviation from linearity by including a quadratic term in the multi-
variable adjusted models.
For each woman, person-years of follow-up were calculated from
the date of return of the baseline questionnaire to the date of first end-
point, death, loss to follow-up, or to 2 March 2009, whichever came
first. Age-adjusted models were further adjusted for smoking, systolic
blood pressure, body mass index, history of diabetes mellitus, HDL-C,
LDL-C, exercise, alcohol consumption, and race/ethnicity. Cumulative
probabilities of incident AF across inflammation score categories were
estimated using the Kaplan–Meier method. Event rates across cat-
egories were compared using the log-rank test. Cox proportional
hazards models were constructed to evaluate the association
between incident AF and inflammation using inflammation score
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categories or principal component parameters either as continuous
variables or categorized into quartiles, respectively.
Even though the population was free of cardiovascular disease at
baseline, an association between inflammation and incident AF may
be caused by intercurrent cardiovascular events, given the strong
relationship between inflammation and cardiovascular
disease.15,20,21,26 We therefore refitted all Cox proportional hazards
models after censoring women at the date of their first confirmed
myocardial infarction, stroke, or coronary revascularization.19
Categorical variables were entered in the Cox models using binary
indicator variables. Tests for linear trend were performed by assigning
all women the tertile-specific median value for each biomarker. Effect
modification was assessed using multiplicative interaction terms and
likelihood ratio tests. The proportional hazards assumption was exam-
ined for all models by including a biomarker by logarithm of time inter-
action into the model.27 No violation of this assumption was detected.
All analyses were carried out using SAS version 9 (SAS Institute, Inc.,
Cary, NC). A two-tailed P-value ,0.05 was considered to indicate
statistical significance.
Results
The median (interquartile range) age of the 24 734 women was 53
(49–59) years. During a median follow-up (interquartile range) of
14.4 (13.8–14.8) years, 747 women experienced a first incident AF
event. Median plasma levels of high-sensitivity C-reactive protein,
sICAM-1, and fibrinogen were 2.0 (0.8–4.3) mg/L, 342 (300–
393) ng/mL, and 350 (307–402) mg/dL. Spearman correlation
coefficient was 0.29 for the association between high-sensitivity
C-reactive protein and sICAM-1, 0.41 for the association
between high-sensitivity C-reactive protein and fibrinogen, and
0.27 for the association between sICAM-1 and fibrinogen,
suggesting weak to moderate correlations between the three
biomarkers. When the study population was divided into tertiles
of the inflammatory parameters, the cut-off values for the
highest tertiles were 3.4 mg/L for high-sensitivity C-reactive
protein, 373 ng/mL for sICAM-1, and 382 mg/dL for fibrinogen.
After summing the number of inflammatory parameters in the
highest tertile, 9640 women (39.0%) had a score of zero, 7876
(31.8%) a score of 1, 4909 (19.9%) a score of 2, and 2309
(9.3%) a score of 3. Baseline characteristics of the study population
stratified by inflammation score categories are shown in Table 1.
Results for the individual biomarkers are shown in Table 2.
When we assessed high-sensitivity C-reactive protein, sICAM-1,
and fibrinogen as log-transformed continuous variables, all bio-
markers were significantly associated with AF in the fully adjusted
model (Table 2). HRs (95% CIs) per increase in 1 standard devi-
ation were 1.11 (1.02–1.21), P ¼ 0.02, 1.11 (1.02–1.20), P ¼
0.02, and 1.10 (1.02–1.20), P ¼ 0.02 for high-sensitivity C-reactive
protein, sICAM-1, and fibrinogen, respectively. Models including a
quadratic term provided no evidence of a curvilinear relationship
between any of the three biomarkers and incident AF. Tertile-
specific analyses showed a gradual increase of incidence rates
from 1.62 to 2.77 events per 1000 person-years for high-sensitivity
C-reactive protein, from 1.84 to 2.67 events for sICAM-1, and
from 1.95 to 2.68 events for fibrinogen. After multivariable
adjustment, HRs (95% CIs) of incident AF among women in the
highest tertile compared with those in the lowest tertile were
1.32 (1.07–1.63) for high-sensitivity C-reactive protein, 1.31
(1.08–1.60) for sICAM-1, and 1.18 (0.97–1.44) for fibrinogen.
Table 3 displays the results using the combined inflammation
score. This score partitioned women into four groups with a
gradually increasing risk of incident AF, as shown in Figure 1. Differ-
ences in event rates across inflammation score categories were
statistically highly significant (P, 0.0001). Similarly, age-adjusted
incidences gradually increased from 1.66 to 3.25 events per 1000
person-years from the lowest to the highest inflammation score
category (Table 3). This trend was attenuated after controlling
for cardiovascular risk factors, but remained statistically significant
(P ¼ 0.0006). The multivariable adjusted HR (95% CI) for women
with an inflammation score of 3 was 1.59 (1.22–2.06). Among
established risk factors, adjustment for body mass index resulted
in the greatest attenuation in the association between the inflam-
mation score and AF [HR (95% CI) 1.0, 1.23 (1.01–1.50), 1.31
(1.06–1.63), and 1.57 (1.22–2.03); P-trend 0.0005]. Again, there
was no evidence of a curvilinear relationship (Table 3). Similar
results were obtained when the inflammation score was based
on biomarker-specific median values (2 mg/L for high-sensitivity
C-reactive protein, 342 ng/mL for sICAM-1, and 350 mg/dL for
fibrinogen). The multivariable adjusted HRs (95% CIs) for
women with a score of 0, 1, 2, and 3 were 1.0, 1.37 (1.04–1.79),
1.49 (1.14–1.95), and 1.68 (1.26–2.23), respectively (P for linear
trend across categories ¼ 0.0006). Our findings were not signifi-
cantly altered when 45 women who had a cardiovascular event
prior to the occurrence of AF were censored from the analysis
[multivariable adjusted HR (95% CI) 1.0, 1.24 (1.01–1.51), 1.30
(1.04–1.63), and 1.52 (1.16–2.01) for women with a score of
zero, one, two and three; p linear trend 0.003].
Similar findings were also obtained, when we used the first com-
ponent of a principal components analysis as a summary measure
of inflammation. The first principal component explained 55% of
the total common variation between the three biomarkers.
Similar to the inflammation score, there was a significant relation-
ship between the extent of inflammation as measured by the first
principal component and incident AF. The HR (95% CI) per 1 stan-
dard deviation increase of the first principal component was 1.29
(1.19–1.39), P, 0.0001 and 1.17 (1.07–1.28), P ¼ 0.0005 after
age and multivariable adjustment, respectively. Fully adjusted HRs
(95% CIs) across increasing quartiles of the first principal com-
ponent were 1.0, 1.54 (1.20–1.98), 1.49 (1.15–1.94), and 1.57
(1.20–2.06). Again, we did not find evidence for a curvilinear
relationship.
Subgroup analyses revealed consistent results across strata of
age, body mass index, systolic blood pressure, diabetes, LDL-C,
and HDL-C. Accordingly, none of the inflammation score by sub-
group interaction terms was statistically significant (all P for inter-
action .0.05).
Discussion
This study indicates that inflammation, as jointly measured by
plasma levels of high-sensitivity C-reactive protein, sICAM-1, and
fibrinogen, is significantly associated with the risk of incident AF
in a female population free of cardiovascular disease at baseline,
suggesting that inflammation may confer an increased risk of
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Table 1 Baseline characteristics according to inflammation score categories
Characteristic Inflammation score P-value
0 (n5 9640) 1 (n 5 7876) 2 (n 5 4909) 3 (n5 2309)
Age (years) 51 (48–56) 54 (49–59) 55 (50–61) 55 (50–61) ,0.0001
Body mass index (kg/m2) 23.3 (21.6–25.7) 25.0 (22.6–28.2) 27.1 (24.0–31.1) 29.3 (25.7–33.7) ,0.0001
Current smoking 4.9 12.2 15.9 23.5 ,0.0001
History of diabetes 0.8 2.1 4.2 8.5 ,0.0001
History of hypercholesterolemia 22.3 31.1 36.4 38.3 ,0.0001
Alcohol consumption ,0.0001
Rarely/never 36.5 43.6 51.3 55.6
1–3 drinks per month 12.7 13.6 14 13.4
1–6 drinks per week 37.6 32.8 27.3 24.7
≥1 drink per day 13.2 10 7.5 6.3
Systolic blood pressure ,0.0001
,120 mmHg 56.9 44.7 34.1 26.2
120–139 mmHg 36.3 43.5 48.3 48.7
≥140 mmHg 6.7 11.8 17.6 25.1
Highest education level ,0.0001
Less than a bachelor’s degree 47.9 55.8 60.6 63.8
Bachelor’s degree 27 23.5 21.3 21
Master’s degree or doctorate 25.1 20.7 18.1 15.2
Exercise (times/week) ,0.0001
Rarely/never 30 37 43.2 50.8
,1 18.6 19.5 21.1 20.4
1–3 36.5 32.4 27.7 22.9
.3 15 11.1 8 5.9
High-sensitivity C-reactive protein (mg/L) 0.9 (0.4–1.7) 2.1 (1.0–3.8) 4.6 (2.9–7.0) 7.0 (4.9–14.4)
sICAM-1 (ng/mL) 307 (277–336) 351 (310–396) 386 (342–433) 433 (401–489)
Fibrinogen (mg/dL) 314 (281–343) 354 (315–395) 405 (368–445) 446 (412–497)
Data are median (interquartile range) or percentages. sICAM-1, soluble intercellular adhesion molecule-1.
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incident AF that is independent of clinically manifest cardiovascular
disease. In this large cohort of women free of cardiovascular
disease at baseline, a high inflammation score was a significant pre-
dictor of incident AF after adjustment for other cardiovascular risk
factors. These results were consistent when other measures were
used to define inflammation, suggesting that our findings were not
dependent on the cut-off chosen to create the score.
Although it has long been recognized that inflammation post-
cardiac surgery may lead to post-operative AF,28,29 whether inflam-
mation plays a causal role in AF development in other settings as
well is more controversial. Inflammatory infiltrates, myocyte
necrosis, and fibrosis have been found in atrial biopsies of patients
with both lone and non-valvular AF,30,31 and chronic inflammation
may induce electrophysiological and structural changes in the atrial
myocardium that may predispose patients with triggering atrial foci
to both the development and persistence of AF.13 In agreement
with these pathologic findings, high-sensitivity C-reactive protein
levels and other markers of inflammation have been found to be
higher in patients with AF when compared with those without in
retrospective studies.11,12,32 However, as inflammatory markers
were measured at the time of or after the diagnosis of AF in
these studies, the temporal relationship is unclear, and thus inflam-
matory marker elevations may be a consequence rather than a
cause of AF.
Several prospective cohort studies, which reduce the potential
for this type of bias, have reported associations between individual
markers of inflammation and AF. Together with our own, three
prospective cohort studies involving different populations have
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Table 2 Tertiles of inflammatory parameters and risk of incident atrial fibrillation
Tertile 1 Tertile 2 Tertile 3 Plinear trend Continuous
a P
High-sensitivity C-reactive protein (mg/L) ≤1.1 1.1–3.4 .3.4
Number of events 162 258 327
Age-adjusted incidence rateb 1.62 2.19 2.77
Age-adjusted HR (95% CI) Referent 1.38 (1.13–1.68) 1.76 (1.45–2.12) ,0.0001
Multivariable adjusted HR (95% CI)c Referent 1.20 (0.98–1.47) 1.32 (1.07–1.63) 0.02 1.11 (1.02–1.21) 0.02
sICAM-1 (ng/mL) ≤315 315–373 .373
Number of events 179 247 321
Age-adjusted incidence rateb 1.84 2.14 2.67
Age-adjusted HR (95% CI) Referent 1.19 (0.98–1.44) 1.48 (1.23–1.78) ,0.0001
Multivariable adjusted HR (95% CI)c Referent 1.10 (0.90–1.31) 1.31 (1.08–1.60) 0.005 1.11 (1.02–1.20) 0.02
Fibrinogen (mg/dL) ≤322 322–382 .382
Number of events 192 224 331
Age-adjusted incidence rateb 1.95 1.99 2.68
Age-adjusted HR (95% CI) Referent 1.02 (0.84–1.24) 1.33 (1.11–1.60) 0.0007
Multivariable adjusted HR (95% CI)c Referent 1.01 (0.83–1.23) 1.18 (0.97–1.44) 0.07 1.10 (1.02–1.20) 0.02
HR, hazard ratio; CI, confidence interval; sICAM-1, soluble intercellular adhesion molecule-1.
aPer increase in one biomarker-specific standard deviation (log-transformed).
bPer 1000 person-years of follow-up.
cAdjusted for age, smoking, systolic blood pressure, body mass index, history of diabetes mellitus, HDL-C, LDL-C, exercise, alcohol consumption, and race/ethnicity. Due to
missing covariates, the multivariable model was based on 722 events in 23 781 women.
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Table 3 Inflammation score and risk of incident atrial fibrillation
Inflammation score
0 1 2 3 Plinear trend Pnonlinear trend
Number of events 190 248 196 113
Age-adjusted incidence ratea 1.66 2.22 2.73 3.25
Age-adjusted HR (95% CI) Referent 1.34 (1.11–1.63) 1.58 (1.29–1.93) 2.04 (1.62–2.59) ,0.0001 0.74
Multivariable adjusted HR (95% CI)b Referent 1.22 (1.00–1.49) 1.32 (1.06–1.65) 1.59 (1.22–2.06) 0.0006 0.84
HR, hazard ratio; CI, confidence interval.
aPer 1000 person-years of follow-up.
bAdjusted for age, smoking, systolic blood pressure, body mass index, history of diabetes mellitus, HDL-C, LDL-C, exercise, alcohol consumption, and race/ethnicity. Due to
missing covariates, the multivariable model was based on 722 events in 23 781 women.
D. Conen et al.1734
found that high-sensitivity C-reactive protein levels were directly
associated with AF incidence. The risk estimates observed for high-
sensitivity C-reactive protein in our apparently healthy population
are similar to those previously reported in the Cardiovascular
Health Study [HR (95% CI) 1.31 (1.08–1.58)]13 and the Framing-
ham Study [HR (95% CI) 1.25 (1.07–1.45)],14 where a proportion
of participants had prevalent cardiovascular disease. With regard
to fibrinogen levels, we found a much more modest association
than that previously reported in a Danish study18 using hospitalized
AF as the endpoint, which likely included more severe cases of AF.
Finally, to our knowledge, our study is the first to have found a sig-
nificant association between sICAM-1 and AF. In one prior pro-
spective study utilizing a smaller number of AF events, an HR of
1.08 (95% CI 0.91–1.28) was observed,17 which would be consist-
ent with the HR of 1.11 (1.02–1.20) observed in the present
analysis with a larger number of events. These findings may
suggest that endothelial dysfunction could have a role in the
pathogenesis of AF.33
The simultaneous examination of multiple inflammatory bio-
markers may provide a more comprehensive picture of the
complex inflammatory process34 and allow for more complete
estimates of the association between inflammation and AF. Pre-
viously, a panel of 12 inflammatory biomarkers was found to be sig-
nificantly associated with incident AF in another analysis from the
Framingham Heart Study utilizing 148 incident AF events.17
However, these relationships were markedly attenuated and
became non-significant after adjusting for interim myocardial
infarction or heart failure.17 Another prospective study performed
exclusively among apparently healthy men and women16 found a
strong association with only 99 AF events when a combination
of high C-reactive protein and complement levels was examined.16
We now confirm these latter results utilizing a combination of
three inflammatory biomarkers in a much larger population of
women free of cardiovascular disease at baseline, where the
association persists even when women with interim cardiovascular
events were censored from the analysis. Taken together, these
prospective studies suggest that chronic inflammation may have a
pro-arrhythmic effect and lead to the development of AF in sus-
ceptible individuals.
Strengths of the present study include its prospective design,
sample size, and long-term follow-up with a large number of con-
firmed events. Potential study limitations that require discussion
are the following: First, we included initially healthy, middle-aged
female health professionals, most of whom are Caucasian, and gen-
eralizability to other populations may be limited. Second, screening
electrocardiograms were not performed in this cohort. Therefore, it
is possible that asymptomatic AF cases may have gone undetected.
However, the number of asymptomatic AF cases in this cohort of
health professionals (n ¼ 74, 9.9%) was very similar to the
number of asymptomatic cases detected by screening electrocardio-
grams in other population-based cohort studies.35 Third, our analysis
was based on a single baseline determination of each plasma marker,
and events occurred over an extended follow-up up to 15.8 years.
Our inability to account for changes in these markers over time may
have limited our power to detect small-to-moderate relative risks.
Fourth, only three inflammatory biomarkers were available for
analysis in this study. Although they are among the best evaluated
markers in association with cardiovascular disease,15,20,21,26 we
might have obtained different results if other or more inflammation
markers had been assessed. Fifth, as with any observational study,
the significant association between inflammation and AF could be
due to residual confounding by other factors, such as undetected
subclinical cardiac disease, and may not imply causality.36 Sixth, the
4324 women from the original cohort who opted out of the obser-
vational follow-up were excluded from this analysis because their AF
could not be reliably confirmed. However, very similar results were
obtained when we repeated our analyses using self-reported AF
events among all women as the main outcome variable (data not
shown). Finally, given that medical records on AF were not obtained
until 2006, some of the medical records were obtained retrospec-
tively. However, information on potential endpoints and all
exposure variables were collected prospectively, and medical
record review was performed without knowledge of exposure
status.
Conclusion
In this prospective study, markers of inflammation were indepen-
dently associated with incident AF in initially healthy, middle-aged
women, even after controlling for traditional risk factors. These
findings suggest that inflammation may be involved in the patho-
genesis of AF.
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